Caris Life Sciences

Caris Life Sciences, founded in 2008, is a leader in the precision medicine sector, specializing in molecular diagnostics and tumor profiling. The company utilizes proprietary artificial intelligence and advanced biotechnology to provide physicians and patients with actionable insights regarding disease treatment. By integrating anatomic pathology with comprehensive molecular testing, Caris Life Sciences delivers high-quality diagnostic services that facilitate personalized healthcare strategies. Their platform supports clinical trials and commercialization efforts, positioning the firm as a critical partner within the global healthcare system.

Operating with a workforce of 1,000-5,000 employees, the organization maintains a robust operational footprint across seven locations. The company’s technical infrastructure enables the processing of complex biological data to drive innovation in oncology and personalized medicine. Meet Caris Life Sciences's team to learn about their leadership and the specialized expertise driving their diagnostic technology development. Their commitment to scientific rigor and data-driven intelligence ensures that healthcare providers receive the most accurate information for patient care, addressing the challenges of modern medicine through scalable, innovative testing solutions.

With annual revenue reaching $989.6M, Caris Life Sciences demonstrates significant market presence and financial stability. The company competes with major industry players such as Foundation Medicine, Guardant, and Illumina, maintaining a competitive edge through continuous investment in proprietary diagnostic technology. Explore financial highlights to review their funding history, including recent debt and equity financing rounds that support their ongoing expansion. As a key entity in the biotechnology landscape, the firm continues to advance the commercialization of precision medicine, leveraging massive datasets to improve patient outcomesView more...